|
Industry
Symposia
| Monday,
October 27 |
| • |
CME
Symposia Breakfast*: Supported
by Watson (6am - 7:30am)
"Effective Testosterone Suppression For Prostate Cancer:
Is There A Best Castration Therapy?"
SPEAKER: Herbert Lepor, M.D. / E. David Crawford,
M.D.
NEEDS
ASSESSMENT:
Prostate
cancer remains the second-leading cause of cancer-related mortality
in the US. Many clinical trials have shown the effectiveness of
androgen suppression therapy against prostate cancer. Androgen suppression
therapy is dose-dependent, with higher levels required to attain
optimal treatment benefit. This optimal benefit requires testosterone
levels at or below castration level in order to diminish the size
and spread of prostate cancer. Consequently, serum testosterone
is measured prior to and during the course of treatment to assess
patient survival rates and outcomes. In certain instances, there
have been reports of a treatment “breakthrough,” an
escape from testosterone suppression indicative of a treatment failure.
Such events indicate continuous challenges in the management of
patients with prostate cancer.
Urologists
benefit from learning about the newest developments in androgen
suppression therapy. This includes information on the dosage-based
efficacy and safety data from current clinical trials. This knowledge
can be applied in medical practice to improve outcomes in patients
with prostate cancer.
|
| • |
CME
Symposia Dinner*: Supported
by Vivus (5:30pm - 8:30 pm)
"Optimizing Penile Rehabilitation After Radical Prostatectomy:
Analysis of the Concept of Cavernosal Oxygenation"
SPEAKERS: Andrew McCullough, M.D. / John Mullhall,
M.D.
NEEDS ASSESSMENT:
High survival rates in men undergoing radical prostatectomy (RP)
have increased the attention given to and the perceived significance
of erectile dysfunction (ED) in this population. ED has a significant
negative impact on the patient's quality of life and self-esteem.
A number of pathophysiologic mechanisms have been implicated in
ED following RP, and nerve-sparing techniques do not appear to
be sufficient to prevent sexual impairment. Even among men in
whom bilateral nerve sparing is achieved, erectile function may
take up to 24 months to return. Aiming to decrease the time to
recovery of spontaneous erections after RP, Montorsi and colleagues
in 1997 pioneered the use of early intracavernosal injections
of alprostadil for penile rehabilitation. The overall concept
of penile rehabilitation is to prevent cavernous tissue damage
during neural recovery, in part by providing adequate oxygenation
to the cavernous tissues. The Montorsi study prompted further
interest in early intervention to ensure the recovery of penile
erections, and the next logical step was to look at oral pharmacotherapy
to restore nocturnal erections as another way to increase oxygenation
of the cavernosal bodies. Although evidence from studies on penile
rehabilitation after RP supports the tissue oxygenation concept,
the rationale and mechanism for its use in penile rehabilitation
programs has not been fully elucidated nor have results been replicated
in large multicenter placebo-controlled trials.
|
| Tuesday,
October 28 |
| • |
CME
Symposia Breakfast*: Supported
by GTx Inc. (6am - 7:30am)
"Emerging Role of Selective Estrogen Receptor Modulators
in Prostate Cancer"
SPEAKER: David I. Quinn, MBBS (Hons), MD, PhD,
FRACP / Samir S. Taneja, MD
NEEDS
ASSESSMENT:
Selective estrogen receptor modulators (SERMs) are an emerging treatment
in the prevention and treatment of adverse effects related to androgen
deprivation therapy (ADT). Used in the treatment of prostate cancer,
androgen deprivation therapy suppresses testosterone levels, consequently
controlling the growth and extent of prostate cancer. However, current
treatments have demonstrated significant adverse effects including
osteoporosis, hot flashes, and gynecomastia.
As
prostate cancer is the second-leading cause of cancer mortality
among males in the US, and HGPIN is the most significant risk factor
for the disease, prostate neoplastic disorders are a significant
healthcare issue. It is imperative for urologists who treat prostate
cancer to learn about the recent advances in disease management
using SERMs for preventing the progression of HGPIN to prostate
cancer, including the role of androgen deprivation therapy, optimal
management of isolated HGPIN, and management of the adverse effects
of ADT.
|
| • |
Non
CME Symposia Lunch*: Supported
by Abbott Laboratories (12pm - 1:30pm)
Promoting Wellness for Your Prostate Cancer Patients
"What Works and What Is Worthless In 2008."
SPEAKER: Mark Moyad, M.D. |
| • |
CME
Symposia Dinner*: Supported
by Gen-Probe (7pm - 9pm)
"Advances in the Diagnosis of Prostate Cancer: The Role
of PCA3"
SPEAKER: Michael Brawer, M.D.
NEEDS
ASSESSMENT:
Prostate cancer is the second leading cause of cancer mortality
in men. In 2008 alone, approximately 186,000 men will be diagnosed
and almost 29,000 men will die from the disease in the United States.1
This disease has been traditionally diagnosed using transrectal
biopsy and biomarkers such as PSA.
Often
patients have elevated biomarker levels but negative findings on
biopsy, complicating diagnosis and management options. Newer biomarkers
such as PCA3 have shown increased accuracy in the monitoring and
diagnosing of prostate cancer, improving present and future patient
outcomes. A program focusing on PCA3 as a diagnostic biomarker should
explain the implications of missing prostate cancer in a biopsy,
discuss factors which may predict missed prostate cancer, evaluate
biomarkers for monitoring and diagnosis, and formulate appropriate
treatment approaches.
|
| Wednesday,
October 29 |
| • |
CME Symposia
Lunch*: Supported by Sanofi~Aventis
(12pm - 1:30pm)
"Maximizing the Clinical Efficacy of Advanced Prostate
Cancer Treatment by Integrating the Specialties: An Interactive,
Case-based Program"
SPEAKERS: E. David Crawford, M.D., Neal Shore,
M.D., David Petrylak, M.D.
To
provide hormone refractory prostate cancer (HRPC) patients with
optimal care, medical oncologists, urologists and radiation oncologists
must be aware of and understand the current treatment options available.
In 2004, a significant advance in the treatment of HRPC occurred
with the FDA approval of docetaxel chemotherapy for the treatment
of metastatic HRPC. This approval was based on improved survival
with docetaxel chemotherapy in the TAX 327 study, a multinational
phase III study comparing mitoxantrone plus prednisone to docetaxel
plus prednisone every 3 weeks and to weekly docetaxel plus prednisone.
Understanding the data from TAX 327 and the administration of docetaxel
is essential if clinicians are to provide evidence-based, standard
of care therapy for patients with symptomatic or asymptomatic, metastatic,
HRPC.
|
(Times
and Events Subject to Change)
|
*
Symposia listed are independent educational programs and not sponsored
by the Western Section AUA. These companies provide support to our
meeting which helps to lower fees. The events are presented in order
to provide attendees with additional learning choices. |
|
